When distinguishing between healthy controls, other liver diseases, and MAFLD, the effects of CK18 M30/M65 and LEAP-2 are not satisfactory; when distinguishing between healthy controls and MAFLD, M65 performed better; when distinguishing between other liver disease controls and MAFLD, LEAP-2 performs better. Here, KRT18 is linked to liver disorder.